

Index

Note: Page numbers of article titles are in **bold face** type.

- ACUTE** leukaemia—
 age distribution of, 6-9
 lymphoblastic, 142
 immunological data, 154
 morphology, 149
 relationship with CLL, 142, 143, 145
 supervening on CLL, 175-176
 survival rates, 145
 myeloid, differentiated from CGL in the
 blastic phase, 106, 108
 Philadelphia chromosome-positive, 68-72
Adrenocorticosteroids, in CLL, 226-227
Agar culture studies, in early detection of the
 blastic phase of CGL, 107-108
Alkylating agents, in CLL, 224-226
 in hairy-cell leukaemia, 252
Anaemia, as prognostic factor in CLL,
 211-212
Autoantibodies in CLL, 195-196
- BCG**, in immunotherapy for CGL, 129-130,
 131, 133, 134, 137
- B-cell lymphocytes**—
 membrane marker identification of, 152,
 169-171
 in CLL, 153-154, 171-178
 monoclonal nature of, 171-173
 differentiation ability of malignant
 clones, 174-175
 origins and functions, 152
- Benzene**, 15, 16, 43-44
- Benzol**, *see* Benzene
- Blastic crisis**, in CGL, 86, *see also*
 Metamorphosis
 acute, in relationship between CLL and
 other lymphoproliferative disorders, 154
 Blastic transformation, *see* Metamorphosis
 and CGL
- Bleomycin**, in CLL, 233
- Busulphan**, in treatment of CGL, 129-133
 in the chronic phase, 116-118
 complications of, 118
- Cell** marker studies, in polymphocytic
 leukaemia, 263
- Cell** marker studies (*continued*)
 in CLL, 169-179
- Cell kinetics**, in CGL, **21-40**
 during phase 1 and 2, 21, 22-23
 during phase 3, 30-36
- Cells**, colony forming, in CGL, 29-30
- Chemical leukaemogens**, *see* Leukaemogens,
 chemical
- Chemotherapy**—
 in CGL, blastic phase, 120-125,
 chronic phase, 116-118
 in CLL, **223-235**
 in hairy-cell leukaemia, 252-253
 in polymphocytic leukaemia, 262-263
Chlorambucil, in CLL, 233
- Chromosome**, Philadelphia, *see* Philadelphia
 chromosome
- Y**, *see* Y chromosome
- Chronic granulocytic leukaemia (CGL)**—
 aetiology, 43-44
 age distribution, 8-9
 atypical presentations, 81-82
 haematological findings, 82
 in Philadelphia chromosome-positive
 patients, 64-65
 physical signs, 82
 survival in, 48
 symptoms, 81
 blastic phase—
 in vitro culture studies in, 107-108
 treatment of, 120
 cell kinetics in, **21-40**
 classical presentation, 77-78
 haematological findings, 78
 physical signs, 77-78
 survival in, 47-48
 symptoms, 77
 chronic phase—
 clinical features of, 113
 cytogenetics of, 59-64, 65-66
 in vitro culture studies, 98-102
 silent, 68-72
 treatment of, 115-120
 clinical aspects, 45-46, 77-95
 active phase, 45-46
 chronic phase, 113

Clinical aspects (*continued*)

- pre-clinical stage, 45
- cytogenetics of, 55-73
 - in chronic phase, 59-64, 65-66
 - in Philadelphia chromosome-negative patients, 65
 - in Philadelphia chromosome-positive patients, with atypical histories, 64-65
 - Philadelphia chromosome-positive cells in blood and marrow, 58-59
- distribution of, 41-43
- evolution of, 35-36
- genetics and, 17-18
- immunotherapy for, 129-139
- in vitro culture studies in, 97-111
 - in chronic phase disease, 98-102
 - in early detection of the blastic phase, 107-108
 - in metamorphosis, 103-107
- laboratory aspects of, 45-46
- less common presentations, 78-81
 - haematological findings, 80-81
 - physical signs, 80
 - symptoms, 79-80
- metamorphosis in, 30-36, 51-52, 67-68, 85-91, 113-115
 - differentiated from acute myeloid leukaemia, 108
 - in vitro studies in, 103-107
 - treatment in, 120-125
- myelofibrosis and, 49-51
- myeloproliferative disorders and, 48-51
- natural history of, 41-53
- pathogenesis, 43-44
- and Philadelphia chromosome, 55-73
 - negative type, 98, 119-120
- racial and social distribution, 10
- silent chronic phase, 68-72
- stable phase, *see* CGL, chronic phase
- survival in, 47-48
 - in atypical cases, 48
 - in typical cases, 47-48
- terminal stage, 91-93
- autopsy findings, 93
- causes of death, 92
- haematological findings, 92
- physical signs, 92
- symptoms, 92
- treatment of, 113-127
 - adverse effects of, 84-85
 - haematological findings, 85
 - physical signs, 85
 - symptoms, 84-85
 - blastic phase
 - in abrupt onset, 120
 - chronic phase, 115-120
 - chemotherapy, 116-118
 - immunotherapy, 119
 - intensive chemotherapy, 124-125

Clinical aspects (*continued*)

- leucapheresis, 119
- splenectomy, 119
- splenic irradiation, 115-116
- in metamorphosis
 - chemotherapy, 120-125
 - in Philadelphia chromosome-negative type, 119-120
- uniclonal theory of origin, 109-110
- well-controlled cases, 82-84
 - haematological findings, 83-84
 - physical signs, 83
 - symptoms, 83
- Chronic leukaemia, epidemiology of, 3-20
 - genetics and, 16-18
- Chronic Leukaemia-Myeloma Task Force (1973), criteria for diagnosis of CLL, 238
- Chronic lymphocytic leukaemia (CLL)—
 - active, definition of, 238
- acute lymphoblastic leukaemia supervening on, 175-176
 - age distribution of, 6-9, 143
 - aetiology, 187
 - as immunoproliferative disorder, 169-184
- B-cell derived, 171-178
 - biclonal processes, 176-177
 - differentiation ability of malignant clone, 174-175
 - lymphocyte stimulation in, 177-178
 - membrane markers in investigation of, 171-178
 - monoclonal nature of, 171-173
- chemotherapy in, 223-235
 - future studies, 233-234
 - present practice, 223-232
 - adrenocorticosteroids, 226-227
 - alkylating agents, 224-226
 - indications for non-intervention, 223-224
 - indications for treatment, 224
 - recommended conventional treatment, 227
 - recent developments in, 232-233
 - other cytotoxic drugs, 233
 - Rai's staging system, 232-233
 - therapeutic hazards, prevention of, 230-232
- classification by B- and T-cell marker analysis, 153-154
- clinical features, 185-202
- complete remission in, 215
- criteria for treatment—
 - by chemotherapy, 223-224
 - by total body irradiation, 238
- definitions, 185
- diagnosis, 185-186, 238
 - differentiated from hairy-cell leukaemia, 247-248
 - differentiated from prolymphocytic leukaemia, 260

Chronic lymphocytic leukaemia (*continued*)

- epidemiology, 187
- genetics and, 17-18, 187
- 'histiocytic' lymphomas supervening on, 154, 175-176
- incidence of other malignancies in, 196-197, 215, 230
- indolent, definition of, 238
- immune phenomena, 194-196
- local irradiation in, 243
- M-2 protocol, 215-219
- morphology, 147
 - scanning electronmicroscope, 147
- natural history of, 143
- pathophysiological analysis of, 188-194
 - local manifestations, 190-193
 - secretory manifestations, 193-194
 - systemic manifestations, 189
- prognostic factors and implications for therapy, 203-222
- racial and social distribution, 10
- radiotherapy as primary treatment in, 237-244
- relationship with other lymphoproliferative disorders, 141-157
 - acute blast crisis, 154
 - clinical and laboratory features in common, 143-145
 - immunological data, 152-154
 - morphology, 145-152
 - Richter's syndrome, 154
- remission, complete, 215
 - following total body irradiation, 240
- resistant, treatment of, 228-230
- sex distribution in, 143
- special aspects, 194-197
- survival rate, 145, 198
 - adenopathy and, 209-211
 - age and, 207
 - anaemia and, 211-212
 - bone-marrow infiltration and, 213
 - following total body irradiation, 240-241
 - hypogammaglobulinaemia and, 214
 - lymphocyte count and, 209
 - M-2 protocol and, 215-219
 - organomegaly and, 211
 - platelet count and, 212
 - sex and, 208
 - symptom duration and, 214
- T-cell derived, 153, 178-179
 - lymphocyte stimulation in, 177-178
- therapy—
 - chemotherapy, 223-234
 - treatment toxicity, 230-232
 - conventional, 227-228
 - value of, 237-238
- indications for non-intervention, 223-224
- indications for treatment, 224
- in relation to pathophysiology, 197

Chronic lymphocytic leukaemia (*continued*)

- indications for intervention, 197
- local irradiation, 243
- radiation, as primary, 237-244
- total body irradiation, clinical trial, clinical material, 239
 - criteria for evaluation of response, 238-239
 - criteria for treatment, 238
 - evaluation of, 242-243
 - infectious and immunological aspects, 241
 - results, 240-241
 - remission induction, 240
 - survival, 240-241
 - treatment schedule, 239-240
 - traditional presentation, 188
 - unusual surface marker phenotypes in, 179
- Colony-forming cells, 29-30, 97
- characteristic abnormalities in leukaemic state, 98-99
- Colony stimulating activity (CSA), *see* Colony stimulating factor
- Colony stimulating factor—
 - defective regulatory control in development of CGL, 100-102
 - functional and biochemical properties of, 100
 - in vitro culture studies in CGL in the blastic phase, 106-107
 - nomenclature, 97
- Corticosteroids, in hairy-cell leukaemia, 252
- Cyclophosphamide—
 - in treatment of CGL, 116
 - in the blastic phase, 120
 - in treatment of CLL, 233
- Cytosine arabinoside, in CLL, 233
- Cytotoxic drugs in hairy-cell leukaemia, 252
- DNA, amount in Philadelphia chromosome, 55
- Daunorubicin in CLL, 233
- Dibromomannitol in the treatment of CGL, 116
- GASTROINTESTINAL tract in CLL, 191
- Genitourinary tract in CLL, 193
- Granulocytes, kinetics of, in CGL, 22-24, 44-45
- Granulocytic leukaemia, chronic, *see* Chronic granulocytic leukaemia
- Granulopoiesis, regulation of—
 - in CGL, 33-34
 - anomalies of, 34-35
 - in non-leukaemic individuals, 32-33
- HAIRY-cell leukaemia, 245-259
 - chemotherapy in, 252-253

Hairy-cell leukaemia (*continued*)

- diagnostic features, 245-248
 - differentiated from CLL, 247-248
- origins of the hairy cell, 253-259
 - morphological and cytochemical aspects, 253-254
 - phagocytic potential, 258-259
 - surface bound immunoglobulins in, 257-258
 - surface receptors, 254-257
- relationship with CLL, 142, 143
 - immunological data, 153
 - morphology, 147
- splenectomy in, 248-251
 - treatment and prognosis, 145, 248-253
- 'Histiocytic' lymphomas supervening on CLL, 175-176
- Hydroxyurea, in treatment of CGL in the blastic phase, 120
- Hypersensitivity syndrome in CLL, 196

I(17q) translocation in CGL, chronic phase, 64
at metamorphosis, 70

Idiopathic cold agglutinin disease, immunological data, 153
relationship with CLL, 142

Immune phenomena in CLL, 194-196

Immune responsiveness and lymphoproliferative disorders, 152-154

Immunotherapy—

- in CGL, 129-139
 - chronic phase, 119
 - clinical course, 133-138
 - effect on mortality rate, 134-135
 - effectiveness of, 136-138
 - immunological responses, 132
 - immunological toxicity, 133, 134, 136

LEUCAPHERESIS in CGL in the chronic phase, 119

Leukaemia—

- acute, *see* Acute leukaemia
 - lymphoblastic, *see* Acute leukaemia, lymphoblastic
 - myeloid, *see* Acute leukaemia, myeloid
- age distribution of, 5-6
- chronic, *see* Chronic leukaemia
 - granulocytic, *see* Chronic granulocytic leukaemia (CGL)
 - lymphocytic, *see* Chronic lymphocytic leukaemia (CLL)
 - monomyelocytic, 48
- hairy-cell, *see* Hairy-cell leukaemia
- incidence of, 4-5
 - temporal changes in, 10-14
- lymphosarcoma-cell, *see* Lymphosarcoma-cell leukaemia

Leukaemia (*continued*)

- prolymphocytic, *see* Prolymphocytic leukaemia
- racial and social distribution, 10
- type distribution, 6-9
 - temporal changes in, 12-13
- Leukaemia clusters, 16
- Leukaemic reticuloendotheliosis, *see* Hairy-cell leukaemia,
- Leukaemogens—
 - chemical, 15, 16, 43-44
 - ionizing radiations, 14-15, 16
 - leukaemia clusters, 16
 - oncogenic viruses, 15, 43
- Liver in CLL, 190-191
- Lungs in CLL, 191-192
- Lymphadenopathy in CLL, 190
- Lymphoma, poorly differentiated lymphocytic, 142, 143, 145
 - well-differentiated lymphocytic, 142, 143, 145
- Lymphoproliferative disorders
 - acute lymphoblastic leukaemia, 142, 143, 145, 154, 175-176
 - classification, 141-143
 - by B- and T-cell markers, 152-154
 - clinical course, 145
 - clinical relationships of, 143-145
 - definition of, 141-143
 - functional relationships of, 152-154
 - hairy-cell leukaemia, 142, 143, 145, 153, 245-259
 - idiopathic cold agglutinin disease, 142, 153
 - morphology of, 145-152
 - multiple myeloma, 142, 143, 145, 153
 - poorly differentiated lymphocytic lymphoma, 142, 143
 - prolymphocytic leukaemia, 144, 145, 147, 153, 260-268
 - relationship to CLL, 141-157
 - common clinical and laboratory features, 143-145
 - well-differentiated lymphocytic lymphoma, 142, 143, 145
 - Waldenström's macroglobulinaemia, 142, 143, 145, 153
- Lymphosarcoma-cell leukaemia, 185
 - chronic, differentiated from CLL, 149
- 6-MERCAPTOPURINE, in treatment of CGL, 116
- M-2 protocol in CLL, 215-219
- Membrane markers of B- and T-cells, 169-171
- Metamorphosis in CGL, 51-52, 85-91
 - acute transformation, 86
 - blastic crisis, 86
 - cell kinetics in, 30-36
 - characteristics of, 113-115
 - chromosomal patterns and, 67-68

- Metamorphosis in CGL (*continued*)
 early detection of in agar culture studies, 107-108
 extramedullary, 91
 haematological findings, 88-90
 missing Y chromosome and, 61
 mixed group, 86
 physical signs, 87-88
 progression of, 91
 splenectomy and, 67
 symptoms, 86-87
- Metamyelocytes, kinetics of in CGL, 24-25
- Mitoclomine in CLL, 233
- Multiple myeloma—
 immunological data, 153
 relationship with CLL, 142, 143, 145
 morphology, 149
 survival rates, 145
- Myeloblasts, kinetics of in CGL, in phase 1 and 2, 28-29
 in phase 3, 30-31
- Myelocytes, kinetics of in CGL, in phases 1 and 2, 25-28
- Myelofibrosis, and CGL, 49-51
- Myeloproliferative disorders, and CGL, 48-51
- NERVOUS system in CLL, 192-193
- ONCOGENIC viruses, 15, 43
- PHILADELPHIA chromosome—
 acquisition, 66
 and origin of terminal blastic clone, 109-110
 translocation and, 56-57
 atypical types, 57-58
 banding techniques, 56
 clonal origin of, 66-67
 DNA in, 55
 distribution of, 66
 duplication in the chronic phase of CGL, 61-64
 history of, 55-58
 identification of, 55-56
 in acute leukaemia, 68-72
 in CGL, atypical histories in, 64-65
 chronic phase, absence of, 65
 cytogenetics of, 59-64
 duplication of, 61-64
 mixed positive and negative cells in, 65-66, 71
 metamorphosis, karyotypes associated with, 67-72
 morphology of, 55
 positive cells in marrow and blood, 58-59
 translocation and, t(Ph¹) type, 57
- Philadelphia chromosome (*continued*)
 duplication of, 61-64
 extra-autosomes and, 61
 lack of Y chromosome in, 60-61
 other rearrangements, 64
- Polycythaemia rubra vera (PRV), progressing to Ph¹-positive CGL, 64
- Poorly differentiated lymphocytic lymphoma, relationship with CLL, 142, 143, 145
- Philadelphia chromosome-negative CGL, 119-120
 in vitro culture, 98
- Prednisolone in hairy-cell leukaemia, 252
- Polymorphocytic leukaemia, 260-268
 cell marker studies, 263
 diagnosis, 260
 relationship with CLL, 144, 145
 immunological data, 153
 morphology, 147
 survival rates, 145
 treatment, 261-263
- RADIATION, ionizing, 14-15, 16
 in CGL, 43
- Radiotherapy for CLL, 237-244
- Rai staging system for CLL, 232-233, 237
 and M-2 protocol, 215-219
 clinical evaluation of, 203-219
³H-thymidine uptake, 214
 adenopathy in, 209-211
 anaemia as prognostic factor in, 211-212
 bone marrow infiltration in, 213
 complete remission in, 215
 family history and incidence of CLL in, 215
 hypogammaglobulinaemia in, 214
 incidence of other malignancies associated with CLL in, 215
 lymphocyte count in, 209
 materials and methods in, 203-204
 median duration of survival in, 205-207
 organomegaly, 211
 patient characteristics, 205-208
 age, 207
 sex, 208-209
 platelets as prognostic factor in, 212
 statistical methods, 204-205
 symptoms, duration of, 214
 treatment, effect on survival in, 214
- Reverse transcriptase, 15, 16
- Richter's syndrome, in CLL, 154, 228-230
- SCANNING electronmicroscopy—
 in CLL, 147
 in hairy-cell leukaemia, 147
- Skeleton, in CLL, 193
- Skin, in CLL, 190

- Spleen, in CLL, 190-191
- Splenectomy in CGL—
 chronic phase, 119
 in delaying metamorphosis in, 67
 in hairy-cell leukaemia, 248-251
 in prolymphocytic leukaemia, 261-262
- Splenic irradiation in CGL in the chronic phase, 115-116
- Surface bound membrane immunoglobulins, (SIg) as B-cell markers, 152-154, 170, 171
 in hairy cells, 257-258
- T-CELL lymphocytes
 cell markers in identification of, 152, 169-171
 in CLL, 178
 lymphocyte stimulation in 177-178
 definition of, 152
- Thioguanine in CLL, 233
- TRAMPCOL (thioguanine, daunorubicin, cytosine arabinoside, methotrexate, prednisone and cyclophosphamide, vincristine
- Trampcol (*continued*)
 and L-asparaginase) regimen in treatment of GLC in blastic phase, 120
- Transmission electronmicroscopy, in diagnosis of hairy-cell leukaemia, 247-248
 in prolymphocytic leukaemia, 147
- Y chromosome, lack of in t(Ph¹) metaphases, 60-61
- VIRUSES, oncogenic, 15, 43
- WELL-differentiated lymphocytic lymphoma, relationship with CLL, 142, 143, 145
 survival rates, 145
- Waldenstrom's macroglobulinaemia, 174, 175
 immunological data, 153
 relationship with CLL, 142, 143, 145
 morphology, 149

Index

Note: Page numbers of article titles are in **bold face type**.

- ACUTE lymphocytic leukaemia—
 - association with HLA, 346–347
 - lymphocyte differentiation markers and, 400–401
- Addison's disease, association with HLA, 343
- Adenosine deaminase deficiency, 424–431
 - biochemical basis of, 427–430
 - clinical aspects, 426–427
 - differentiation from NP deficiency, 432
 - genetic and enzymological aspects, 424–425
 - pyrimidine starvation in, 434
 - immunological aspects, 425–426
 - therapeutic considerations, 430–431
- Agammaglobulinaemia, congenital Bruton-type, 377–380
- Allergic diseases associated with HLA, 346
- Alloantigens—
 - B-cell specific, identification of, 337–338
 - in detection of cell surface differentiation antigens, 367–368
 - HLA, *see* HLA complex
 - human lymphocyte, genetic control and relation to disease, **331–354**
 - transplantation, 331
- Amyloidosis—
 - lymphadenopathy in, 490
 - symptoms, 507
- Angioimmunoblastic lymphadenopathy (AIL), 481–485
- Angiomatous lymphoid hamartoma, 487
- Ankylosing spondylitis, association with HLA, 345–346
- Antibody production—
 - lymphocyte co-operation in, 289–295
 - antihapten antibody responses to hapten-carrier conjugates, 289–290
 - regulation of antigen-non-specific T cells, 441
 - thymus marrow synergism, 289
- Antibody protein system, *see* Immunoglobulins
- Antibodies, characteristics of in secondary response, 286–287
- Antihapten antibody responses to hapten-carrier conjugates, 289–290
- Antigens—
 - differentiation, 367–369, 371–372
 - cell surface, 367–369
 - cytoplasmic and nuclear, 371–372
 - HLA, *see* HLA complex
 - I-region, 332
 - localization in lymph node, 316–318
 - lymphocyte recognition of, 284–287
 - B cells, 285
 - minimum theory of, 284–285
 - subsequent cellular events, 286–287
 - T cells, 285
 - reactive with homogeneous immunoglobulins, 513–514
- Antigenic competition in immunosuppression, 443
- Antigenic stimulation—
 - changes in spleen following, 321
 - changes in lymph node following, 318–320
 - secondary, 287
- Aplasia, pure red cell (PRCA), 380–381
- Arthropathies associated with HLA, 345–346
- Ataxia telangiectasia, 390–391
- Autoantibodies in detection of cell surface antigens, 368
- Autoimmunity—
 - non-antigen-specific suppressor functions in, 444
 - SLE as example of, 464–466
- B CELLS—
 - antigen recognition mechanisms, 285
 - cell surface immunoglobulin on, 385
 - co-operation with T cells, 289–295
 - mechanisms of, 291–295
 - distribution in secondary lymphoid organs, 281
 - Fc receptors and, 361
 - neoplasms of, and relation to immunoglobulin, **503–532**
 - origins, 278
 - sequence of marker development, 356
 - surface markers, 283–284
 - membrane markers in identification of, 304–305

- Bence-Jones proteins—
 structure, 508
 symptoms relating to, 507
- Bronchus-associated lymphoid tissue (BALT),
 322, 324
- Bursa-dependent lymphocytes, *see* B cells
- Bursa of Fabricius—
 role in avian immune response, 278
 role in avian B-cell differentiation, 356
- CARTILAGE-hair hypoplasia, 391
- Cell-mediated immunity—
 antigen-specific suppression of, 451
 cytological events in, 286-287
 definition, 277
 role of thymus in, 278-279
 suppression by T cells, 442-443
- Cell surface differentiation antigens, *see*
 Antigens, differentiation; Cell surface
 markers
- Cell surface immunoglobulin—
 detection techniques, 358-361
 extrinsic, 359-360
- Cell surface markers, 299, 304-305, 357-371
 application to tissue section, 370
 combined marker studies, 370-371
 complement receptors, 362-364
 differentiation antigens, 367-369
 Epstein-Barr virus, 369
 Fc receptors, 361-362
 immunoglobulin, 358-361
 in ataxia telangiectasia, 390-391
 in cartilage-hair hypoplasia, 391
 in combined immunodeficiency, 386-389
 in congenital Bruton-type agammaglobu-
 linaemia, 377-380
 in Di George syndrome, 389-390
 in Down's syndrome, 392
 in immunodeficiency diseases, 377-392
 in monocyte identification, 369-370
 in selective IgA deficiency, 385-386
 in steely-hair syndrome, 392
 in thymoma-immunodeficiency syndromes,
 380-381
 in variable immunodeficiency, 381-385
 in Wiscott-Aldrich syndrome, 391
 in X-linked immunodeficiency with Hyper-
 IgM, 392
 spontaneous erythrocyte rosettes, 364,
 365-366, 366-367
 mouse, 364
 primate, 366-367
 sheep, 365-366
- Cellular immunity, *see* Cell-mediated im-
 munity
- Chronic lymphocytic leukaemia (CLL), dif-
 ferentiation markers in, 393-395
- Clonal selection theory, 284-286, 503
- Celiac disease, association with HLA,
 343-344
- Cold agglutinins, symptoms related to, 506
- Combined immunodeficiency, 386-389
- Complement receptors, 362-364
 detection methods, 362-363
- Congenital Bruton-type agammaglobulin-
 aemia, 377-380
- Connective tissue diseases, lymphadenopathy
 in, 491-495
- Cryoglobulins, symptoms related to, 505-506
- Cytoplasmic differentiation markers, 371-373
 antigens, 371-372
 enzymes, 372-373
- DERMATITIS herpetiformis, association with
 HLA, 343-344
- Di George syndrome, cell surface markers in,
 389-390
- Diabetes mellitus, association with HLA,
 342-343
- Differentiation antigens, *see* Antigens, dif-
 ferentiation
- DNA synthesis, non-antigen-specific suppres-
 sion of, 440-441
- Down's syndrome, 392
- Dysgammaglobulinaemic lymphadenopathy,
 479-501, *see also* Lymphadenopathy
- ENDOCRINOPATHIES associated with HLA,
 342-343
 Diabetes mellitus, 342
 Grave's disease, 343
- Enzymes as differentiation markers, 372-373
- Epstein-Barr virus, as cell surface marker,
 369
- Erythrocyte rosettes—
 in the detection of complement receptors,
 362-363
 mouse, 364
 primate, 366-367
 sheep, 365-366
- FC RECEPTORS, 361-362
 detection methods, 361-362
 immunoregulation, 452-453
- Felty syndrome, lymphadenopathy in,
 491-492
- Fetal liver, role in B-cell development, 356
- GASTROINTESTINAL disorders associated with
 HLA, 343-344
 Celiac disease, 343-344
 Giant lymph node hyperplasia (GLH), 487

- Graft-versus-host reaction—
 lymphadenopathy due to, 496–497
 suppression by T cells, 442–443
Grave's disease, association with HLA, 343
Gut-associated lymphoid tissue, 321–322
- HAIRY cells, latex ingestion in, 369–370
Heavy chain disease—
 differentiation markers in, 395
 proteins in, 518–521, 525
 α -type, 515–516
 proteins in, 520
 γ -type, 514–515
 lymphadenopathy in, 489–490
 proteins in, 518–520
 μ -type, 516–518
 lymphadenopathy in, 490
 proteins in, 520–521
Hereditary orotic aciduria, pyrimidine starvation in, 434
Heteroantibodies, in detection of cell surface antigens, 368–369
Histiocytic medullary reticulosis, 402
HLA complex—
 diseases associated with, 341–347
 allergic, 346
 arthropathies, 345–346
 endocrine, 342–346
 gastrointestinal, 343–344
 malignant, 346–347
 neurological, 344–345
 disease susceptibility, mechanisms of, 347–349
 genetic structure of, 332, 334–339
 histocompatibility typing and disease association, 339–341
 nomenclature, 334–336
Hodgkin's disease—
 association with HLA, 347
 lymphocyte differentiation markers and, 401–402
Humoral immunity—
 cytological events in, 286
 definition, 277
 suppression by T cells, 441–442
Hyperviscosity syndrome, symptoms, 505
Hypoxanthine-guanine phosphoribosyl transferase and Lesch-Nyhan syndrome, 433–434
- I-REGION antigens, 332
IgA deficiency, selective, cell surface markers in, 385–386
Immune response—
 anatomy of, 299–330
 antigen-specific suppression of, 446–452
 and tolerance, 449–451
Immune response (*continued*)
 genetic factors, 447
 in cell-mediated immunity system, 451
 mechanisms of, 451–452
 cell morphology, 300–310
 lymphocyte, 300–305
 mononuclear phagocytes, 308–310
 plasma cells, 305–308
 cellular, *see* Cellular immunity
 cellular basis of, 277–298, 440
 cellular interactions in, 287–296
 between B and T lymphocytes, 289–295
 implications of, 296
 macrophage-lymphocyte, 288–289
 T-cell dependent suppression, 295–296
 cytological response to antigen, 286–287
 Fc-receptor units, role in regulation of, 452–453
 humoral, *see* Humoral immunity
 non-antigen-specific suppression, 440–446
 antigenic competition, 443
 by con-A, 442
 in autoimmunity, 444
 in graft-versus-host reactions, 442–443
 in self-tolerance, 444
 mediators of, 445–446
 of antibody production, 441
 of circulating immunoglobulins, 443–444
 of DNA synthesis, 440–441
 relationship of viruses and lymphoid malignancy in, 458–460
 secondary responses, 286–287
 suppressor cells—
 and malignant diseases, 454–467
 characteristics of, 295–296, 453–454
 thymectomy and, 313
 tumour growth and immunity in experimental animals, 455–457
Immunization, lymphadenopathy due to, 496
Immunodeficiency—
 and malignancy, 460–464
 spectrum from benign to malignant lymphoproliferation, 461–464
 variable, cell surface markers in, 381–385
Immunodeficiency diseases—
 cell surface markers in identification of, 370, 377–392
 ataxia telangiectasia, 390–391
 combined immunodeficiency, 386–389
 congenital Bruton-type agammaglobulinaemia, 377–380
 Di George syndrome, 389–390
 miscellaneous primary immunodeficiencies, 391–392

- Immunodeficiency diseases (*continued*)**
 selective IgA deficiency, 385–386
 thymomas, 380–381
 variable immunodeficiency, 381–385
 due to purine nucleoside phosphorylase deficiency, 431–433
 hereditary orotic aciduria, 434
 Lesch-Nyhan syndrome, 433–434
 lymphocyte differentiation markers and, 355–421
 metabolic basis of and lymphocyte enzyme deficiencies, 423–438
 miscellaneous, primary, cell surface markers in, 391–392
 severe combined, 423–431, *see* Severe combined immunodeficiency disease
 suppressor cells in, 466–467
- Immunoglobulins—**
 abnormal, *see* Immunoglobulins, variants
 assembly of, 521–526
 cell surface, *see* Cell surface immunoglobulin
 circulating, non-specific T-cell suppression of, 443–444
 classification, 503, 504
 distribution of cells synthesizing, 521–522
 relation to B-cell neoplasms, 503–532
 secretion, 503–532
 structure, 503–532
 functional differentiation, 512–513
 genetic factors in, 511–512
 symptoms related to proteins with unusual properties, 504–507
 synthesis, 503–532
 light and heavy chain co-ordination mechanisms, 523
 regulation of, 521–526
 variants, 513–521
 in heavy-chain diseases, 514–518
- Immunological tolerance, 287**
- Immunosuppression—**
 antigen-specific, 446–452
 and tolerance, 449–451
 genetic factors, 447
 in cellular immune system, 451
 mechanisms of, 451–452
 non-antigen-specific, 440–446
 antigenic competition, 448
 by con-A, 442
 in autoimmunity, 444
 in graft-versus-host reactions, 442–443
 in self-tolerance, 444
 mechanisms of, 445–446
 of circulating immunoglobulins, 443–444
 of DNA synthesis, 440, 441
 regulation of antibody production, 441
 suppressor cells
 and malignancy, 454–467
- Immunosuppression (*continued*)**
 in experimental animals, 455–458
 in human studies, 466–467
 and tolerance, 449–451
 characteristics of, 295–296, 453–454
 role in lymphopoietic disorders, 439–478
- Infectious mononucleosis, lymphadenopathy in, 495**
- JUVENILE rheumatoid arthritis, lymphadenopathy in, 492**
- K CELLS, 284, 357**
- Kaposi syndrome, lymphadenopathy in, 491**
- LATEX ingestion, in hairy cells, 369–370**
 in monocytes, 369–370
- Lesch-Nyhan syndrome, defects in B-cell function and, 433–434**
- Leukaemia—**
 acute lymphocytic, *see* Acute lymphocytic leukaemia
 chronic lymphocytic, *see* Chronic lymphocytic leukaemia
 lymphadenopathy in, 490
- Liver cells, fetal, and lymphopoiesis, 278–281, 312**
- Lymph node, 313–320**
 anatomy, 313
 antigen location, site of, 316–318
 morphological changes following antigenic stimulation, 318–320
 small lymphocyte recirculation in, 282
- Lymphadenopathy—**
 angioimmunoblastic (AIL), 481–485
 angiomatous lymphoid hamartoma, 487
 chronic, with systemic manifestations, 481–487
 drug-induced, 496
 dysgammaglobulinaemic, 479–501
 giant lymph node hyperplasia (GLH), 487
 in connective tissue disorders, 491–495
 Felty syndrome, 491–492
 mixed connective tissue disease, 494
 Peetoom-Meltzen syndrome, 494
 rheumatoid arthritis, 491
 juvenile, 492
 Sjögren's syndrome, 495
 systemic lupus erythematosus, 492–494
 in graft-versus-host reaction, 496
 in infectious disease, 495
 in malignant diseases, 487–491
 amyloidosis, 490
 γ-heavy chain disease, 489–490
 μ-heavy chain disease, 490
 kaposi sarcoma, 491

Lymphadenopathy (*continued*)

- leukaemia, 490
- lymphoma, 490–491
- multiple myeloma, 489
- Waldenström's macroglobulinaemia, 489
- in lymphoid granulomatous vasculitis, 496
- in sarcoidosis, 495
- in vaccination and immunization, 495–496
- sinus histiocytosis with massive lymphadenopathy (SHML), 485–487

Lymphocyte differentiation markers—

- application to diseases, 355–421
 - acute lymphocytic leukaemia, 400–401
 - chronic lymphocytic leukaemia, 393–395
 - immunodeficiency states, 377–392
 - lymphoreticular neoplasms, 392–402
- cell surface markers, 299, 304–305, 357–371, *see also* Cell surface markers
- cytoplasmic, 371–373
 - antigens, 371–372
 - enzymes, 372–373
- functional, 374–377
- nuclear, 371–373

Lymphocyte enzyme deficiencies—

- adenosine deaminase, 423, 424–431, *see also* Adenosine deaminase deficiency
- and metabolic basis of immunodeficiency disease, 423–438
- hypoxanthine-guanine phosphoribosyl transferase, 433–434
- orotidyl decarboxylase, 434
- purine nucleoside phosphorylase, 431–433

Lymphocyte surface immunoglobulin, *see* Cell surface immunoglobulin

Lymphocytes—

- antigen recognition in, 284–287
 - cellular events following, 286–287
- atypical, 299
- bursa-dependent (B-cell), *see* B-cell lymphocytes
- cell surface markers, *see* Cell surface markers, Lymphocyte differentiation markers
- classification, 299
 - K cells, 357
 - non-phagocytic monocytes, 357
- co-operation between B and T cells, 289–295
 - mechanisms of, 291–295
- functional classification of 283, 284, 358
- in fetal thymus, 311
- in post-natal thymus, 313
- interactions with macrophages in immune response, 288–289
- morphology of, 300–305
 - electronmicroscopy of, 300–302
 - freeze fracture of, 302–303
 - in mitogen and antigen stimulation, 305

Lymphocytes (*continued*)

- light microscopy and histochemistry, 300
- membrane markers, 299, 304–305, 357–371
 - scanning electronmicroscopy of, 302
- physiology of, 281–284
- recirculation of, 282–283, 324–325
 - B cells, 325
 - functional significance of, 282–283
 - T cells, 324–325
- regulation by T cells, 289–296
 - co-operation with B cells, 289–295
 - implications of, 296
 - suppressive influence, 295–296
- small, function of, 277
- T-cell, *see* T-cell lymphocytes
- Lymphoid granulomatous vasculitis, 496
- Lymphoid organs—
 - primary (central), 278–281, 311
 - differentiation from secondary lymphoid organs, 279–281
 - secondary (peripheral), 281, 311
- Lymphoid system—
 - anatomy of, 278–281, 311
 - gut-associated lymphoid tissue (GALT), 321–322
 - lymph nodes, 313–320
 - primary organs, 278–281
 - pulmonary lymphoid tissue, 322–324
 - secondary organs, 281
 - spleen, 320–321
 - stem-cell pool, 278
 - thymus, 311–313
 - organization of, 311–324
- Lymphoid tissue—
 - gut-associated (GALT), 321–322
 - pulmonary, 322–324
 - bronchus-associated (BALT), 322, 324
 - see also* Spleen, Lymph node, Thymus, Fetal liver
- Lymphokines, 286
- Lymphoma, non-Hodgkin's, differentiation markers and, 396–400
 - lymphadenopathy in, 490–491
- Lymphopoietic disorders, role of suppressor T cells in, 439–478
- Lymphoproliferative diseases—
 - lymphocyte differentiation markers and, 355–421
 - cell surface markers, 370
 - spectrum from benign to malignant, 461–464
- Lymphoreticular neoplasms—
 - differentiation markers in, 392–402
 - acute lymphocytic leukaemia, 400–401
 - chronic lymphocytic leukaemia (CLL), 393–395
 - heavy-chain disease, 395
 - histiocytic medullary reticulosis, 402

- Lymphoreticular neoplasms (*continued*)
 Hodgkin's disease, 401-402
 monocytic leukaemias, 402
 multiple myeloma, 395-396
 non-Hodgkin's lymphomas (solid tissue), 396-400
 Waldenström's macroglobulinaemia (WM), 395
- MACROGLOBULINAEMIA, Waldenström's *see* Waldenström's macroglobulinaemia
- Macrophages—
 differentiation from B and T cells, 283-284
 interactions with lymphocytes, 288-289
 morphology of, 310
 plasma membrane receptors, 310
 properties, 284
- Malignant disease—
 associated with HLA, 346-347
 Hodgkin's disease, 347
 immunodeficiency states and, 460-461
 lymphadenopathy in, 487-491
 role of immune response to viruses in, 458-460
 suppressor cells and, 454-467
- Monoclonal proteins, interaction with other cells and serum proteins, 507
- Monocytes—
 circulating, morphology of, 309-310
 identification of, 369-370
 non-phagocytic, 357
 plasma membrane receptors, 310
- Monocyte macrophage, *see* Mononuclear phagocyte
- Monocytic leukaemias, differentiation markers and, 402
- Mononuclear cell population—
 identification of, 357-377
 cell surface markers, 357-371
 cytoplasmic and nuclear differentiation markers, 371-373
 functional cell markers, 374-377
 morphology, 373-374
 electron microscopy, 374
 light microscopy, 373-374
- Mononuclear phagocytes—
 definition, 308-309
 plasma membrane receptors, 310
- Multiple myeloma—
 lymphadenopathy in, 489
 lymphocyte differentiation markers in, 395-396
- Multiple sclerosis, association with HLA, 344-345
- Myasthenia gravis, association with HLA, 345
- Myeloma proteins, 513-514, 524-525
- NEOPLASMS, lymphoreticular, *see* Lymphoreticular neoplasms of B cells, relation to immunoglobulin, 503-532
- Neurological disorders associated with HLA, 344-345
 multiple sclerosis, 344-345
- Nuclear differentiation markers, 371-373
 antigens, 371-372
 enzymes, 372-377, *see also* Cell surface markers
- Nucleoside phosphorylase (NP) deficiency, *see* Purine nucleoside phosphorylase deficiency
- Null cells, immunoglobulins on, 358, 360
- OROTIC aciduria, hereditary, 434
- PEETOOM-MELTZER syndrome, lymphadenopathy in, 494
- Peyer's patches, 321-322
- Phagocytosis, 369-370
- Plasma cells—
 electronmicroscopy, 306
 histochemistry, 306
 light microscopy, 306
 morphology, 305-308
- Purine metabolism deficiencies—
 adenosine deaminase, 424-431
 hypoxanthine-guanine phosphoribosyl transferase, 433-434
 purine nucleoside phosphorylase, 431-433
- Purine nucleoside phosphorylase (NP) deficiency, 431-433
 clinical and immunological aspects, 431-432
 differentiation from adenosine deaminase deficiency, 432
 genetics and enzymology, 432-433
 metabolic basis of immunodeficiency, 433
 therapy, 433
- Pulmonary lymphoid tissue, 322-324
- RECEPTORS—
 complement, 362-364
 Fc, 361-362
- Reiter's syndrome, association with HLA, 345
- Rheumatoid arthritis—
 association with HLA, 346
 lymphadenopathy in, 491
- Rosettes, spontaneous erythrocyte—
 mouse, 365
 primate, 366-367
 sheep, 365-366
- SARCOIDOSIS, lymphadenopathy in, 495

- Selective IgA deficiency, cell surface markers in, 385-386
- Self-tolerance, 444
- Severe combined immunodeficiency disease, 423-431
- biochemical basis of, 427-430
 - clinical aspects, 426-427
 - genetic and enzymological aspects, 424-425
 - immunological aspects, 425-426
 - therapeutic considerations, 430-431, *see also* Adenosine deaminase deficiency
- Sinus histiocytosis with massive lymphadenopathy (SHML), 485-487
- Sjögren's syndrome, lymphadenopathy in, 495
- Solid tissue (non-Hodgkin's) lymphomas, 396-400
- Spleen—
- immune functions of, 320-321
 - recirculation of lymphocytes in, 282, 324-325
- Steely-hair syndrome, 392
- Stem cells, role in immune response, 278, 280
- Surface membrane markers, *see* Cell surface markers
- Systemic lupus erythematosus, 404-466
- lymphadenopathy in, 492-494
 - suppressor T cells in, 444-445
- T CELLS—**
- activated, 286
 - antigen recognition mechanisms, 285-286
 - characteristic properties, 283-284
 - co-operation with B cells, 289-295
 - mechanisms of, 291-295
 - differentiation markers and, 304-305, 362-369
 - cell surface, 283, 284
 - sequence of development, 357
 - distribution in secondary lymphoid organs, 281
 - origins of, 278, 312
 - recirculation of, 324-325
 - T, subset, 324
 - T, subset, 324
 - suppressor, 295-296, 439-478
- T CELLS (continued)**
- and malignancy, 454-467
 - and tolerance, 449-451
 - characteristics, 295-296, 453-454
 - role in lymphopoietic disorders, 439-478
- Telangiectasia, ataxia, cell surface markers in, 390-391
- Third and fourth pharyngeal pouch syndrome, *see* Di George syndrome
- Third population cells, 375
- complement receptors and, 362
 - Fc receptors and, 361, 362
 - immunoglobulins on, 358, 360
- Thymoma-immunodeficiency syndromes, 380-381
- Thymus, 311-313
- fetal, lymphocytes in, 311
 - postnatal, lymphocytes in, 313
 - role in cellular immunity, 278-281
 - thymectomy and immune function, 313
- Thymus-dependent lymphocytes, *see* T cells
- Thymus marrow synergism in antibody production, 284
- Tolerance, 444-451
- Transfer factor, 286
- Tumour growth in experimental animals—
- genetic factors in, 457-458
 - immune response and, 455-456
- VACCINATION, lymphadenopathy in, 495
- Variable immunodeficiency, adenosine deaminase deficiency in, 425-426
- Viruses, role in immune response and lymphoid malignancy, 458-460
- WALDENSTRÖM'S macroglobulinaemia—
- differentiation markers in, 395
- lymphadenopathy in, 489
- Waldeyer's ring, 321
- Wiscott-Aldrich syndrome, 391
- X-LINKED immunodeficiency with hyper-IgM, 392

Index

Note: Page numbers of article titles are in **bold face** type.

- ALLOGENEIC RED CELLS, survival studies on, 617-618
- Anaemia—
 - iron kinetics and erythropoiesis in, 590-591
 - haemolytic, 591
 - megaloblastic, 590-591
 - megaloblastic—
 - iron kinetics and erythropoiesis in, 590-591
 - isotopes in, **719-730**
 - use of folates in, 724-728
 - use of vitamin B₁₂ in, 719-724
 - of pregnancy, blood volume measurement in, 559
 - refractory hypoplastic, application of ferrokinetic measurements in, 593
- Ascorbic acid, use of with ⁵¹Cr, 607
- Atherogenesis, 687-689
- Autoradiographic methods, in diagnosis and analysis of dyserythropoiesis, 665-667
- BLOOD VOLUME—
 - clinical usefulness of measurements of—
 - in haematology, 551-555
 - in non-haematological diseases, 555-559
 - anaemia of pregnancy, 559
 - cardiovascular pathology, 555
 - chronic renal disease, 556
 - cirrhosis, 559
 - endocrine diseases, 558-559
 - in surgical patients, 559
 - malnutrition, 559
 - respiratory pathology, 555
 - in health and disease, **543-566**
 - methodology, 544-547
 - normal values and expression of results, 547-549
 - physiological variations in normal values, 549-550
 - regulation of, long-term, 551
 - short-term, 550-551
- ¹¹C-CARBON MONOXIDE, in direct measurement of red cell volume, 545
- Cardiovascular pathology, blood volume measurement in, 555
- Chronic renal disease, blood volume measurement in, 556
- Cirrhosis, blood volume measurement in, 559
- Cohort labelling techniques, 603-604
- ⁵¹Cr—
 - as a red cell label, 604-605
 - elution of, 605-606
 - label uptake by young cells, 606-607
 - relative advantages and disadvantages of DFP and, 608-609
 - use of ascorbic acid with, 607
- ⁵¹Cr-labelled red cells, in clinical use for quantitative radioisotope scanning, 631-633
- DEEP VEIN THROMBOSIS of the legs, methods of diagnosis, 731-734
- Deoxyuridine suppression test, in diagnosis of megaloblastosis, 724-725
- DFP (DF³²P)—
 - as a red cell label, 607-609
 - relative advantages and disadvantages of ⁵¹Cr and, 608-609
- Dyserythropoiesis—
 - autoradiographic methods in, 665-667
 - ferrokinetics, 660-663
 - isotopes in the clinical investigation of, **657-670**
 - labelled haemoglobin precursors (other than iron), use of, 664-665
 - radioisotope methods for diagnosis and analysis of, 660-667
 - red cell survival studies and ferrokinetics in, 664
 - red cell turnover in, estimation of, 663-664
- ENDOCRINE DISEASES, blood volume measurement in, 558-559
- Erythrocyte iron turnover (EIT), evaluation of, 588-589, 597
- Erythropoiesis—
 - and iron kinetics, 589-591
 - in haemolytic anaemia, 591
 - in megaloblastic anaemia, 590-591
 - in normal man, 589-590

Erythropoiesis (*continued*)

- isotopes in the clinical investigation of, 657-660
 - dyserthropoiesis, 659-660
 - ineffective erythropoiesis, 658-659
 - normal erythropoiesis, 657-658
- labelling transferrin, 583-584
- radioiron and, methods of interpretation and clinical application, 583-599
- Extrinsic labelling, in food iron absorption, 575-576

⁵⁹Fe—

- plasma clearance curve, 584-587
- red cell uptake, 587-588

Ferroketic measurements—

- application of, 592-593
 - iron deficiency, 592-593
 - refractory hypoplastic anaemia, 593
- evaluation of, 593-597
 - erythrocyte iron turnover (EIT), 597
 - plasma iron clearance rate, 594-595
 - plasma iron turnover (PIT), 595-596
 - red cell ⁵⁹Fe utilization, 597

Ferroketic studies—

- in clinical use of quantitative radioisotope scanning, 633-634
- in diagnosis and analysis of dyserthropoiesis, 660-663
 - plus red cell survival studies, 664

Fibrinogen metabolism in disease, alterations in, 739-740

Fibrinogen turnover, 736-742

- and of other plasma constituents and platelets, 740-742

Fibrinogen uptake test—

- in monitoring deep vein thrombosis, 732-733
- other suggested uses, 736

Folates, use of in megaloblastic anaemia, 724-728

Food iron absorption, 573-576

- extrinsic labelling in, 575-576
- haem, 574
- inorganic (non-haem), 574

GRANULOCYTE KINETICS in health and disease, 695-717, *see* Neutrophil kinetics

HAEMOGLOBIN PRECURSORS (other than iron), labelled, in diagnosis and analysis of dyserthropoiesis, 664-665

Haemolytic anaemia, iron kinetics and erythropoiesis in, 591

Heat damaged red cells—

- clearance studies in spleen function, 641-642
- in clinical use of quantitative radioisotope scanning, 634-635

IDIOPATHIC THROMBOCYTHAEMIA, 685

International Committee for Standardization in Haematology (ICSH), Panel on diagnostic application of radioisotopes in haematology, 745-750

aims and membership, 745-746

future activities, 749

recommendations in preparation, 748-749

recommended methods for radioisotope red cell survival studies, 748

recommended methods for surface counting to determine sites of red-cell destruction, 748

standard techniques for the measurement of red-cell and plasma volume, 747-748

Iron absorption—

clinical applications of radioisotope methodology, 576-578

dietary factors, 576-577

impaired, 577

increased, 577-578

mucosal iron transport, 579

clinical measurements of, 567-581

radioisotope methodology, 568-571

faecal, 568-569

plasma, 568

red cell incorporation, 569-570

whole body counting, 570-571

food, 573-576

variability in, 571-573

biological, 572-573

method of statistical analysis, 573

physiological, 572

Iron deficiency, application of ferroketic measurements, 592-593

Iron kinetics—

and erythropoiesis, 589-591

in haemolytic anaemia, 591

in megaloblastic anaemia, 590-591

in normal man, 589-590

recommendation of ICSH panel on diagnostic application of radioisotopes in haematology, 748-749

Iron turnover—

erythroid, 588-589

non-erythroid, 589

Isotopes, *see* Radioisotopes

LABELLING—

extrinsic, 575-576

transferrin, 583-584

MALNUTRITION, blood volume measurement in, 559

Mean cell lifespan (MCL)—

derivation of, in red cell survival studies, 610-611

estimates from ferroketic data, 619

- Megakaryocytopoiesis, in platelet production in man, 671-672
- Megaloblastic anaemia—
 iron kinetics and erythropoiesis, 590-591
 isotopes in, 719-744
 use of folates in, 724-728
 use of vitamin B₁₂ in, 719-724
- Megaloblastosis, deoxyuridine suppression test in diagnosis of, 724-725
- NEUTROPENIA, 707-709
- Neutrophil kinetics, normal, 696-706
 comparison of methods, 706
 study methods, 696
 clinical usefulness of, 709-711
- Neutrophil leucocytosis, 706-707
- Neutrophil production, cell kinetics in non-malignant disorders of, 706-709
- Non-haematological diseases, clinical usefulness of measurement of blood volume in—
 anaemia of pregnancy, 559
 cardiovascular pathology, 555
 chronic renal disease, 556
 cirrhosis, 559
 endocrine diseases, 558-559
 malnutrition, 559
 respiratory pathology, 555
 surgical patients, 559
- ³²P-SODIUM PHOSPHATE, in direct measurement of red cell volume, 544
- Panel on diagnostic application of radioisotopes in haematology, 745-750
- Plasma ⁵⁹Fe clearance curve, 584-587
 interpretation of, 585-586
 analysis of, 586-587
- Plasma iron clearance rate, evaluation of, 594-595
- Plasma iron turnover (PIT), evaluation of, 595-596
- Plasma volume—
 changes in splenomegaly, 649
 direct measurement of, 546-547
- Platelet kinetics, 671-693
 destruction in man, 676-682
 platelet labelling, 677
 random labelling, 677-678
 survival, analysis of data, 680-682
 measurements, 678-680
 disorders of, 682-685
 thrombocytopenia, 682-684
 thrombocytosis, 684-685
 production in man, 671-676
 formation of, 672-674
 measurements of, 674-676
 megakaryocytopoiesis, 671-672
 regulation of, 676
- Pregnancy, blood volume measurement in anaemia of, 559
- Pulmonary embolism, diagnosis of, 734-736
- QUANTITATIVE RADIOISOTOPE SCANNING, and its use in haematology, 625-637
 calculation of uptake in the organ, 628-629
 calibration of the scanner, 627-628
¹⁵Cr-labelled red cells, studies with, 631-633
 ferrokinetic studies, 633-634
 heat damaged red cells, studies with, 634-635
 principles of, 626-627
 procedure for scanning the patient, 628
 splenic red cell pool, 630-631
 technique, 626-629
- RADIOIRON and erythropoiesis, methods, interpretation and clinical application, 583-599
- Radioisotopes—
 clinical applications, 752
 in dyserythropoiesis, 657-670
 in iron absorption studies, 568-571, 576-578
 a faecal measurement, 568-569
 a plasma measurement, 568
 red cell incorporation measurement, 569-570
 whole-body counting, 570-571
 in megaloblastic anaemia, 719-730
 ICSH panel on diagnostic application of, 745-750
 physical characteristics of, 751-756
 scanning, quantitative, and its use in haematology, 625-637
- Random labelling techniques, 604-609
 derivation of mean cell lifespan, 610-611
 interpretation of data obtained from, 609-615
- Red cell—
 allogeneic, survival studies on, 617-618
 direct measurement of volume, 544-545
¹¹C-carbon monoxide in, 545
⁵¹Cr-sodium chromate in, 544
 errors and limitations of, 545-546
³²P-sodium phosphate in, 544
⁹⁹Tc^m-pertechnetate, 544
⁵⁹Fe uptake, 587-588
⁵⁹Fe utilization, evaluation of, 597
 heat-damaged, 634-635, 641-642
- Red cell and plasma volume, ICSH standard techniques for the measurement of, 747-748
- Red cell destruction, ICSH recommended methods for surface counting to determine sites of, 748

- Red cell survival curve, 611–615
- Red cell survival studies, reinterpreted, **601–623**
- allogeneic, 617–618
 - cohort labelling techniques, 603–604
 - historical review, 601–602
 - ICSH recommended radioisotope methods for, 748
 - interpretation of data obtained in random labelling techniques, 609–615
 - practical aspects of data interpretation, 616–617
 - random labelling techniques, 604–609
- Red cell turnover, estimation of in diagnosis and analysis of dyserythropoiesis, 663–664
- Red cell volume, measurement of in spleen function, 643–646
- Refractory hypoplastic anaemia, application of ferrokinetic measurements in, 593
- Renal disease, chronic, blood volume measurement in, 556
- Respiratory pathology, blood volume measurement in, 555
- SCINTILLATION SCANNING—**
- of the spleen with radioisotope labelled red cells, 639–641
 - splenic atrophy, 641
- Spleen function, 639–656**
- clearance studies using heat-damaged red cells, 641–642
 - measurement of red cell volume, 643–646
 - scintillation scanning with radioisotope labelled red cells, 639–641
- Splenectomy, indications for, 652–653
- Splenic atrophy, in scintillation scanning, 641
- Splenic erythropoiesis—
- assessment of, 649–653
 - indications for splenectomy, 652–653
- Splenic red cell destruction, the quantitation of, 646–648
- Splenic red cell pool—
- estimation in measurement of red cell volume, 643–644
 - in clinical use of quantitative radioisotope scanning, 630–631
- Splenic red cell volume—
- blood flow, 643
 - variations in measurement of, 644–646
- Splenomegaly, plasma volume changes in, 649
- Surgical patients, blood volume measurement in, 559
- ⁹⁹Tc^m-PERTECHNATE, in direct measurement of red cell volume, 544
- Thrombocytopenia, 682–684
- Thrombocytosis, autonomous, 685
- reactive, 684–685
- Thromboembolic disease, **731–744**
- Thrombogenesis, and its prevention, 685–687
- Thrombosis, deep vein, methods of diagnosis, 731–734
- Transferrin labelling, in erythropoiesis, 583–584
- VENOUS THROMBOSIS** in the legs, methods of diagnosis, 731–734
- Vitamin B₁₂, use of in megaloblastic anaemia, 719–724

X
g,

on
ell
oe

n,
nt
nt

7
s,
s,
of
a,